Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
23.82
-0.99 (-3.99%)
Aug 29, 2025, 10:49 AM - Market open
Dianthus Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts that cover Dianthus Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $54, which forecasts a 126.70% increase in the stock price over the next year. The lowest target is $40 and the highest is $84.
Price Target: $54 (+126.70%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Dianthus Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 3 | 3 | 3 | 3 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Maintains $34 → $42 | Buy | Maintains | $34 → $42 | +76.32% | Aug 21, 2025 |
| William Blair | William Blair | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Jul 2, 2025 |
| Wedbush | Wedbush | Buy Maintains $36 → $34 | Buy | Maintains | $36 → $34 | +42.74% | May 13, 2025 |
| Baird | Baird | Buy Maintains $58 → $50 | Buy | Maintains | $58 → $50 | +109.91% | May 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +67.93% | May 13, 2025 |
Financial Forecast
Revenue This Year
2.92M
from 6.24M
Decreased by -53.25%
Revenue Next Year
2.53M
from 2.92M
Decreased by -13.24%
EPS This Year
-3.50
from -2.55
EPS Next Year
-3.71
from -3.50
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 7.1M | 7.5M | |||
| Avg | 2.9M | 2.5M | |||
| Low | 1.3M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 14.4% | 156.9% | |||
| Avg | -53.2% | -13.2% | |||
| Low | -78.7% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.29 | -3.08 | |||
| Avg | -3.50 | -3.71 | |||
| Low | -3.75 | -4.82 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.